NEW YORK--(BUSINESS WIRE)--IntelliCell BioSciences, Inc. (OTCQB: SVFC) (PINKSHEETS: SVFC) (“IntelliCell” or the “Company”), a leader in regenerative medicine and the manufacturing of stromal vascular fraction (SVF) containing adipose derived adult stem cells, announced today that it has signed an agreement with Philadelphia based Numoda Capital Innovations, an investment arm of Numoda Corporation, pursuant to which Numoda Capital has agreed to become an investor in the Company which will be aimed at bringing faster, more cost effective clinical trials to the university level.
